Understanding CLVS1: A Potential Drug Target and Biomarker (G157807)

Target Name: CLVS1

NCBI ID: G157807

CLVS1

Understanding CLVS1: A Potential Drug Target and Biomarker

CLVS1 (Clavesin-1) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the family of transmembrane proteins known as clavins, which are characterized by the presence of a characteristic transmembrane domain and a unique topology of intracellular loops. CLVS1 is unique among clavins in that it is the only known protein that contains a heptadecameric C-terminal domain, which is a type of intracellular loop that is involved in protein-protein interactions and may function as a scaffold to organize the cytoskeleton.

The function of CLVS1 is not well understood, but it is thought to play a role in various physiological processes in the body. CLVS1 is involved in the regulation of cell adhesion, as it is known to interact with the protein known as E-cadherin. This interaction may be important for the regulation of tissue repair and regeneration. Additionally, CLVS1 is involved in the regulation of cell survival and proliferation, as it is known to play a role in the negative regulation of the survival signaling pathway.

Due to its involvement in these processes, CLVS1 has been identified as a potential drug target. Researchers have identified several potential small molecules that can inhibit the activity of CLVS1, and these molecules have been tested in a variety of cellular and animal models of disease. One of these molecules, known as JS-5233, has been shown to inhibit the activity of CLVS1 and to reduce the migration of cancer cells.

Another potential drug target for CLVS1 is the protein known as PDGF-BB. PDGF-BB is a potent signaling molecule that is involved in the regulation of cell growth, differentiation, and survival. It is thought to play a role in the development and progression of many diseases, including cancer. CLVS1 has been shown to interact with PDGF-BB, and this interaction may be important for the regulation of cell survival and proliferation. Therefore, compounds that can inhibit the activity of CLVS1 may be a useful tool for the treatment of diseases associated with high levels of PDGF-BB.

In addition to its potential as a drug target, CLVS1 is also a potential biomarker. The cytoskeleton is a complex structure that is involved in the regulation of many cellular processes, including cell division, migration, and cytoskeleton organization. Therefore, the cytoskeleton can be used as a readout for the health and function of cells. CLVS1 is a well-known protein that is involved in the regulation of the cytoskeleton, and its levels can be used as a marker for the health and function of cells.

In conclusion, CLVS1 is a protein that is involved in the regulation of various cellular processes in the body. Its unique topology and the presence of a heptadecameric c-terminal domain make it a unique member of the clavin family. While the full function of CLVS1 is not well understood, it is thought to play a role in the regulation of cell adhesion, survival, and proliferation. As a result, CLVS1 is a potential drug target and a potential biomarker for a variety of diseases. Further research is needed to fully understand the role of CLVS1 in the regulation of cellular processes and to develop effective treatments for the associated diseases.

Protein Name: Clavesin 1

Functions: Required for normal morphology of late endosomes and/or lysosomes in neurons (By similarity). Binds phosphatidylinositol 3,5-bisphosphate (PtdIns(3,5)P2)

The "CLVS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CLVS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets